Neoantigen Peptide Services
Vaccines that activate the immune system play a key role in the prevention and treatment of human diseases. The development of cancer vaccines, however, have only been effective in virus-caused cancers such as human papillomavirus-induced cervical cancers. It has long been known that T cells play important roles in recognition and control of tumor cells (2001, Shankaran). Harnessing T-cells to target and kill specific cancer cell types (i.e., immunotherapy) has emerged at the forefront of novel cancer therapeutics. Traditional immunotherapy approaches involving the targeting of existing tumor epitopes has had limited success mainly due to the low T-cell avidity from thymic selection and central tolerance. The limited success of traditional immunotherapies outside of the viral-induced cancer types has created additional opportunities for new therapies to emerge.
In order to increase the quality and T-cell binding affinity of the tumor epitopes, researches began targeting 'neoepitopes' that result from non-synonymous mutations. During progression and carcinogenesis, tumors acquire random mutations [i.e., tumor-specific antigens (TSAs)] that are not encoded by the normal tumor genome. The mutations result in proteins that may serve as 'neoantigens' which are not subject thymic selection and central tolerance. T-cells that recognize tumor neoantigens are therefore likely to have high avidity.
Neoantigen Overview Video
Immunotherapy- The Path To A Cancer Cure (For Clinicians)
This YouTube video and it's producers are not affiliated with CPC Scientific Inc.
Created by Dr. Samir N. Khleif (Georgetown Lombardi Comprehensive Cancer Center), in partnership with the Society for Immunotherapy of Cancer (SITC) and Cancer Support Community, IMMUNOTHERAPY: The Path to a Cancer Cure explains the interplay between the immune system and cancer; mechanisms underlying immune-based agents; and different approaches to cancer immunotherapeutics. Patients: Watch the Patient version of this video here: https://www.youtube.com/watch?v=afdq8Op-jQM
CPC Scientific Neoantigen Services (PeptiVacTM)
The individualized nature of neoantigen immunotherapy typically requires 10-30 GMP-grade peptides (selected as neoantigens) to be manufactured for each patient. Peptide neoantigen therapy constitutes a significant paradigm-shift in GMP peptide manufacturing due to the need for multiple unique peptide sequences targets and rapid synthesis, quality control, and release. With these changes in mind, CPC Scientific has launched our new PeptiVacTM neoantigen manufacturing platform:
- All neoantigen peptides are produced in our GMP manufacturing facilities.
- Multiple isolated GMP suites dedicated to neoantigen peptide synthesis, purification, and isolation.
- Rapid manufacturing, quality control, and release
- Turn around time for each project varies; however, most neoantigen projects can be completed within 3 weeks
Neoantigen Peptide Reference Articles:
- Carreno, Beatriz M., Vincent Magrini, Michelle Becker-Hapak, Saghar Kaabinejadian, Jasreet Hundal, Allegra A. Petti, Amy Ly et al. "A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells." Science 348, no. 6236 (2015): 803-808.
- Khong, Hiep, Annika Volmari, Meenu Sharma, Zhimin Dai, Chinonye S. Imo, Yared Hailemichael, Manisha Singh et al. "Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response." The Journal of Immunology (2018): ji1700467.
- Ott, Patrick A., Zhuting Hu, Derin B. Keskin, Sachet A. Shukla, Jing Sun, David J. Bozym, Wandi Zhang et al. "An immunogenic personal neoantigen vaccine for patients with melanoma." Nature 547, no. 7662 (2017): 217.
- Yarchoan, Mark, Burles A. Johnson III, Eric R. Lutz, Daniel A. Laheru, and Elizabeth M. Jaffee. "Targeting neoantigens to augment antitumour immunity." Nature Reviews Cancer 17, no. 4 (2017): 209.